World Journal of Gastroenterology - Baishideng Publishing Group

BPG is committed to discovery and dissemination of knowledge

Cited by in CrossRef

For:	Zhu K, Kakkar R, Chahal D, Yoshida EM, Hussaini T. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease. World J Gastroenterol 2023; 29(37): 5327-5338 [PMID: 37899788 DOI: 10.3748/wjg.v29.i37.5327]
URL:	https://www.wjgnet.com/1007-9327/full/v29/i37/5327.htm

(180) (189) (0) (0) (0) (1) (2) (14974) (41)

Number	Citing Articles
1	Rong Ren, Yanxia Pei, Lufei Kong, Yixin Shi. The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease. Journal of Diabetes and its Complications 2025; 39(2) doi: 10.1016/j.jdiacomp.2024.108932
2	Mohit Kehar, Samar H. Ibrahim, Charina M. Ramirez, Saista Asif Amin, Tamir Diamond, Saeed Mohammad. Utilization and perspectives of weight loss medications in pediatric metabolic dysfunction‐associated steatotic liver disease. Journal of Pediatric Gastroenterology and Nutrition 2024; 79(3) doi: 10.1002/jpn3.12236
3	Omnia A. Hawary, Walaa Wadie, Yasmin A. M. El-Said, Omnia F. Hassan. Repurposing of semaglutide by targeting SIRT1 and TGF‐β/Smad signaling in hepatic fibrosis. Naunyn-Schmiedeberg's Archives of Pharmacology 2026; 399(3) doi: 10.1007/s00210-025-04675-x
4	Matthew Peverelle, Jonathan Ng, James Peverelle, Ryan D. Hirsch, Adam Testro. Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis. World Journal of Gastroenterology 2023; 29(47): 6165-6167 doi: 10.3748/wjg.v29.i47.6165 Abstract(903) \| Core Tip(1069) \| Full Article(HTML)(7023) \| Full Article (PDF)-656K(350) \| Full Article with Cover (PDF)-4462K(249) \| Full Article (Word)-227K(37) \| Full Article (XML)-26K(187) \| Audio-304K(26) \| Peer-Review Report-234K(157) \| Answering Reviewers-232K(148) \| Times Cited (11) \| Total Visits (8377) \| Open
5	Fabiana Dolovitsch de Oliveira, Samira Mohamad Khalil, Emmily Daiane Buarque de Santana Sato, Matheus Henrique Gonçalves de Souza, Gilmara Coelho Meine. Efficacy and Safety of Fibroblast Growth Factor 21 Analogues for Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis. Annals of Nutrition and Metabolism 2024; doi: 10.1159/000541583
6	François Briand, Caroline Dubroca, Guillaume Wettstein, Estelle Grasset, Natalia Breyner, Claire Bigot, Rana Assaly, Pierre Broqua, Thierry Sulpice. Lanifibranor and semaglutide demonstrate multiple metabolic benefits in free-choice diet induced obese hamster models of MASH and MetALD. European Journal of Pharmacology 2025; 1003 doi: 10.1016/j.ejphar.2025.177945
7	Hui Wu, Zi-Heng Zhang, Ting Ye, Jia-Ni Chen, Tao-Hsin Tung, Jian-Sheng Zhu. Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review. Frontiers in Medicine 2026; 13 doi: 10.3389/fmed.2026.1783429
8	Hong-Tai Tzeng, Wei-Chia Lee. Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity. Nutrients 2024; 16(9) doi: 10.3390/nu16091388
9	Amedeo Lonardo, Ralf Weiskirchen. Liver and obesity: a narrative review. Exploration of Medicine 2025; 6 doi: 10.37349/emed.2025.1001334
10	Shu Niu, Shu-Chun Chen, Chen-Xi Wang, Lin Yue, Shu-Qi Wang. Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice. World Journal of Hepatology 2025; 17(10): 110402 doi: 10.4254/wjh.v17.i10.110402 Abstract(90) \| Core Tip(67) \| Full Article(HTML)(289) \| Full Article (PDF)-22459K(86) \| Full Article with Cover (PDF)-22772K(91) \| Full Article (XML)-117K(36) \| Audio-188K(12) \| Peer-Review Report-284K(35) \| Answering Reviewers-111K(44) \| Times Cited (0) \| Total Visits (575) \| Open
11	D. M. Antsiferova, O. M. Koteshkova, M. B. Antsiferov. Have we done everything possible for a patient with type 2 diabetes mellitus combined with obesity?. Meditsinskiy sovet = Medical Council 2025; (16) doi: 10.21518/ms2025-446
12	Moaz Safwan, Mariam Safwan Bourgleh, Shahad Abdullah Alotaibi, Eman Alotaibi, Abdulsalam Al-Ruqi, Fathiya El Raeya. Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis. Annals of Saudi Medicine 2025; 45(2) doi: 10.5144/0256-4947.2025.129
13	Xiao‐yan You, Xiang‐yang Li, Hui Wang, Guo‐ping Zhao. Development of NAFLD‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation. Cell Proliferation 2026; 59(4) doi: 10.1111/cpr.70118
14	Farah Khaznadar, Omar Khaznadar, Ana Petrovic, Marija Hefer, Fabian Gjoni, Stefan Gjoni, Justinija Steiner, Martina Smolic, Kristina Bojanic. MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development. Current Issues in Molecular Biology 2024; 46(7) doi: 10.3390/cimb46070376
15	V. T. Ivashkin, O. M. Drapkina, M. V. Maevskaya, K. L. Raikhelson, S. V. Okovityi, M. S. Zharkova, V. R. Grechishnikova, D. I. Abdulganieva, S. A. Alekseenko, M. D. Ardatskaya, I. G. Bakulin, N. V. Bakulina, P. O. Bogomolov, V. V. Breder, E. V. Vinnitskaya, N. I. Geyvandova, E. V. Golovanova, V. B. Grinevich, V. L. Doshchitsin, E. N. Dudinskaya, E. V. Ershova, K. B. Kodzoeva, I. V. Kozlova, K. A. Komshilova, Yu. V. Konev, N. V. Korochanskaya, Yu. V. Kotovskaya, Yu. A. Kravchuk, I. D. Loranskaya, I. V. Maev, A. I. Martynov, S. N. Mekhtiev, E. E. Mishina, M. Yu. Nadinskaia, I. G. Nikitin, M. F. Osipenko, O. D. Ostroumova, Ch. S. Pavlov, N. V. Pogosova, V. G. Radchenko, G. E. Roytberg, R. G. Saifutdinov, A. A. Samsonov, P. V. Seliverstov, S. I. Sitkin, L. V. Tarasova, A. I. Tarzimanova, O. N. Tkacheva, E. I. Tkachenko, E. A. Troshina, S. V. Turkina, Yu. P. Uspenskiy, Yu. A. Fominykh, O. V. Khlynova, Yu. V. Tsyganova, M. Sh. Shamkhalova, O. O. Sharkhun, M. V. Shestakova. Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2025; 35(1) doi: 10.22416/1382-4376-2025-35-1-94-152
16	Husam Albarmawi, Firas Dabbous, Abdalla Aly, Alia Yousif, Samuel Huse, Maximilian Jara, Andres Quintero, Eric Lawitz. Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide. Current Medical Research and Opinion 2025; 41(11) doi: 10.1080/03007995.2025.2596430
17	Yasser Fouad, Wafaa A Abdelghany, Reem El Sheemy. Anti-obesity medications, the new frontiers in metabolic dysfunction-associated fatty liver disease: Efficacy, limitations, and future directions. World Journal of Hepatology 2026; 18(5): 118303 doi: 10.4254/wjh.v18.i5.118303 Abstract(42) \| Core Tip(38) \| Full Article(HTML)(126) \| Full Article (PDF)-11877K(20) \| Full Article with Cover (PDF)-12124K(11) \| Full Article (XML)-161K(10) \| Audio-1594K(2) \| Peer-Review Report-209K(10) \| Answering Reviewers-98K(9) \| Times Cited (0) \| Total Visits (243) \| Open
18	Jahnavi Udaikumar, Rithish Nimmagadda, Vindhya Vasini Lella, Kesava Manikanta Achuta, Satwik Kuppili, Suraj Reddy Avula, Raiya Sarwar. The Comparative Safety and Efficacy of Resmetirom and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review. Pharmacoepidemiology 2025; 4(3) doi: 10.3390/pharma4030014
19	Ermina Stratina, Carol Stanciu, Robert Nastasa, Sebastian Zenovia, Remus Stafie, Adrian Rotaru, Tudor Cuciureanu, Cristina Muzica, Catalin Sfarti, Irina Girleanu, Horia Minea, Oana Petrea, Laura Huiban, Stefan Chiriac, Ana-Maria Singeap, Oana Vlad, Camelia Cojocariu, Anca Trifan. New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease. Diagnostics 2024; 14(14) doi: 10.3390/diagnostics14141475
20	Devaraj Ezhilarasan. Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?. Journal of Gastroenterology and Hepatology 2025; 40(9) doi: 10.1111/jgh.17037
21	Sultan Alfawaz, Abdulhadi Burzangi , Ahmed Esmat. Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review. Cureus 2024; doi: 10.7759/cureus.67080
22	Fatima Ali Raza, Rafiya Altaf, Talha Bashir, Fatima Asghar, Rabiya Altaf, Sohaib Tousif, Aman Goyal, Aisha Mohammed, Mahnoor Faisal Mohammad, Mahfuza Anan, Sajjad Ali. Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review. Medicine 2024; 103(44) doi: 10.1097/MD.0000000000040364
23	Tereza Dusilová, Jan Kovář, Ivana Laňková, Lenka Thieme, Monika Hubáčková, Petr Šedivý, Dita Pajuelo, Martin Burian, Monika Dezortová, Denisa Miklánková, Hana Malínská, Petra Svobodová Šťastná, Rudolf Poledne, Milan Hájek, Martin Haluzík. Semaglutide Treatment Effects on Liver Fat Content in Obese Subjects with Metabolic-Associated Steatotic Liver Disease (MASLD). Journal of Clinical Medicine 2024; 13(20) doi: 10.3390/jcm13206100
24	Kathryn J Potter, Jackie Phinney, Tasha Kulai, Vicki Munro. Effects of GLP-1 receptor agonist therapy on resolution of steatohepatitis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Journal of the Canadian Association of Gastroenterology 2025; 8(2) doi: 10.1093/jcag/gwae057
25	Megan O. Bensignor, Silva Arslanian, Mary Ellen Vajravelu. Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice. Current Opinion in Pediatrics 2024; 36(4) doi: 10.1097/MOP.0000000000001365
26	Antonio Saviano, Natascha Roehlen, Thomas F. Baumert. Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma. Seminars in Liver Disease 2024; 44(02) doi: 10.1055/s-0044-1785646
27	Giovanna McGinty, Robert Przemioslo. Effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease: Clinical implications. World Journal of Gastroenterology 2024; 30(27): 3264-3267 doi: 10.3748/wjg.v30.i27.3264 Abstract(792) \| Core Tip(805) \| Full Article(HTML)(2554) \| Full Article (PDF)-359K(275) \| Full Article with Cover (PDF)-1163K(228) \| Full Article (XML)-59K(151) \| Audio-772K(31) \| Peer-Review Report-171K(127) \| Answering Reviewers-104K(142) \| Times Cited (6) \| Total Visits (3208) \| Open
28	Maria Zasadzińska, Grzegorz Borowski, Piotr Bakuła, Kamila Jałocha. The Evolving Role of GLP-1 Receptor Agonists in MASLD: Current Evidence and Future Directions. Journal of Diabetology 2025; 16(3) doi: 10.4103/jod.jod_18_25
29	E.E. Mulyukova, E.L. Novikova, I.A. Skirdov, K.S. Usmanova, N.V. Yusifzade. Pharmacotherapy of the metabolically associated fatty liver disease. Russian Journal of Preventive Medicine 2025; 28(10) doi: 10.17116/profmed202528101103
30	Tzu‐Rong Peng, Hung‐Hong Lin, Tzu‐Ling Tseng, Ta‐Wei Wu, You‐Chen Chao. Clinical evidence of semaglutide for metabolic dysfunction‐associated steatotic liver disease (MASLD): An updated meta‐analysis. British Journal of Clinical Pharmacology 2026; doi: 10.1002/bcp.70629
31	Iris van de Loo, Birgit Harbeck. Facharztwissen Endokrinologie und Diabetologie. 2026; doi: 10.1007/978-3-662-71684-7_12
32	L. B. Lazebnik, S. V. Turkina, E. V. Golovanova. Targeted use of hepatoprotectors for the treatment of various stages of non-alcoholic fatty liver disease (fatty degeneration of the liver according to ICD 10) and associated comorbid conditions; tables for medical use. Experimental and Clinical Gastroenterology 2024; (10) doi: 10.31146/1682-8658-ecg-230-10-11-35
33	Klaudia Nowak, Krzysztof Łupina, Anna Romac, Aleksandra Kalisz, Łucja Ilkiewicz, Jakub Janczura. Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease. Annals of Pharmacotherapy 2025; 59(10) doi: 10.1177/10600280251322002
34	Sofia Rozani, Maria Dalamaga, Georg Weber, Robert Grützmann. Liver transplantation in the era of obesity: A metabolic public health crisis meets a surgical frontier. Metabolism Open 2025; 28 doi: 10.1016/j.metop.2025.100410
35	Connor Endsley, Shariq Ali, Karim Salhadar, Adam Woodward, Shea Garland, Julien Santelli, Mehdi Zeighami Salimabad, Liqiang Ren, Takeshi Yokoo, Ivan M. Rosado‐Mendez, David T. Fetzer, Caroline de Gracia Lux. Lipid Microparticle‐Based Phantoms Modeling Hepatic Steatosis for the Validation of Quantitative Imaging Techniques. Small Methods 2025; 9(8) doi: 10.1002/smtd.202500043
36	Mohamed Mahmoud Marey, Mohamed Belal, Abdelaziz A. Awad, Eslam Mohammed Rabea, Malak A. Hassan, Ahmed W. Abbas, Abdulqadir J. Nashwan. Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology 2024; 48(6) doi: 10.1016/j.clinre.2024.102357
37	Roberta Chianetta, Lydia Giannitrapani, Alessio Giuseppe Lipari, Assunta Brunone, Claudia Cannizzo, Roberto Citarrella, Maurizio Soresi, Antonio Liguori, Nadia Panera, Filomena Morisco, Luca Miele, Anna Licata. Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease. Biomolecules 2026; 16(6) doi: 10.3390/biom16060797
38	Emir Muzurović, Martin Haluzik, Ludek Horváth, Bogdan Vlacho, Didac Mauricio. Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease. Current Pharmaceutical Design 2026; 32(20) doi: 10.2174/0113816128378484250619080753
39	Pattern of Glycemic Status of Chronic Liver Disease Patients. TAJ: Journal of Teachers Association 2025; 38(4) doi: 10.70818/taj.v38i04.0434
40	Yue-Hua Yin, Li-Xuan Sang, Bing Chang. Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1. World Journal of Gastroenterology 2023; 29(48): 6235-6238 doi: 10.3748/wjg.v29.i48.6235 Abstract(921) \| Core Tip(849) \| Full Article(HTML)(3554) \| Full Article (PDF)-349K(278) \| Full Article with Cover (PDF)-822K(190) \| Full Article (Word)-106K(46) \| Full Article (XML)-49K(201) \| Audio-235K(31) \| Peer-Review Report-231K(163) \| Answering Reviewers-55K(131) \| Times Cited (4) \| Total Visits (4269) \| Open
41	Samira Mohamad Khalil, Matheus Henrique Gonçalves de Souza, Fabiana Dolovitsch de Oliveira, Emmily Daiane Buarque de Santana Sato, Gilmara Coelho Meine. Efficacy and safety of aldafermin for the treatment of metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2025; 49(5) doi: 10.1016/j.clinre.2025.102579